Recent progress of chemotherapy and biomarkers for gastroesophageal cancer
|
摘要
Key cytotoxic drugs of chemotherapy for gastroesophageal cancer include fluoropyrimidine, platinum, taxanes and irinotecan. Concurrent chemoradiotherapy is one of the main treatment strategies, especially for esophageal cancer. As molecular target agents, the anti-HER2 antibody trastuzumab for HER2-positive gastric cancer and the anti-angiogenesis agent ramucirumab combined with paclitaxel have been proven to improve the survival of gastric cancer patients. Recently, anti-PD-1 antibodies have become available as second-or later-line chemotherapy. Microsatellite instability is also useful as a biomarker to select patients suitable for immunotherapy.Furthermore, genome-wide analysis has improved our understanding of the biological features and molecular mechanisms of gastroesophageal cancer and will provide optimized treatment selection.
Key cytotoxic drugs of chemotherapy for gastroesophageal cancer include fluoropyrimidine, platinum, taxanes and irinotecan. Concurrent chemoradiotherapy is one of the main treatment strategies, especially for esophageal cancer. As molecular target agents, the anti-HER2 antibody trastuzumab for HER2-positive gastric cancer and the anti-angiogenesis agent ramucirumab combined with paclitaxel have been proven to improve the survival of gastric cancer patients. Recently, anti-PD-1 antibodies have become available as second-or later-line chemotherapy. Microsatellite instability is also useful as a biomarker to select patients suitable for immunotherapy.Furthermore, genome-wide analysis has improved our understanding of the biological features and molecular mechanisms of gastroesophageal cancer and will provide optimized treatment selection.
Key cytotoxic drugs of chemotherapy for gastroesophageal cancer include fluoropyrimidine, platinum, taxanes and irinotecan. Concurrent chemoradiotherapy is one of the main treatment strategies, especially for esophageal cancer. As molecular target agents, the anti-HER2 antibody trastuzumab for HER2-positive gastric cancer and the anti-angiogenesis agent ramucirumab combined with paclitaxel have been proven to improve the survival of gastric cancer patients. Recently, anti-PD-1 antibodies have become available as second-or later-line chemotherapy. Microsatellite instability is also useful as a biomarker to select patients suitable for immunotherapy.Furthermore, genome-wide analysis has improved our understanding of the biological features and molecular mechanisms of gastroesophageal cancer and will provide optimized treatment selection.
引文
1 Smyth EC,Verheij M,Allum W,Cunningham D,Cervantes A,Arnold D;ESMO Guidelines Committee.Gastric cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up.Ann Oncol2016;27:v38-v49[PMID:27664260 DOI:10.1093/annonc/mdw350]
2 Koizumi W,Narahara H,Hara T,Takagane A,Akiya T,Takagi M,Miyashita K,Nishizaki T,Kobayashi O,Takiyama W,Toh Y,Nagaie T,Takagi S,Yamamura Y,Yanaoka K,Orita H,Takeuchi M.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial):a phase IIItrial.Lancet Oncol 2008;9:215-221[PMID:18282805 DOI:10.1016/S1470-2045(08)70035-4]
3 Al-Batran SE,Hartmann JT,Probst S,Schmalenberg H,Hollerbach S,Hofheinz R,Rethwisch V,Seipelt G,Homann N,Wilhelm G,Schuch G,Stoehlmacher J,Derigs HG,Hegewisch-Becker S,Grossmann J,Pauligk C,Atmaca A,Bokemeyer C,Knuth A,J?ger E;Arbeitsgemeinschaft Internistische Onkologie.Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin:a study of the Arbeitsgemeinschaft Internistische Onkologie.J Clin Oncol 2008;26:1435-1442[PMID:18349393 DOI:10.1200/jco.2007.13.9378]
4 Kang YK,Kang WK,Shin DB,Chen J,Xiong J,Wang J,Lichinitser M,Guan Z,Khasanov R,Zheng L,Philco-Salas M,Suarez T,Santamaria J,Forster G,McCloud PI.Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phase IIInoninferiority trial.Ann Oncol 2009;20:666-673[PMID:19153121 DOI:10.1093/annonc/mdn717]
5 Cunningham D,Starling N,Rao S,Iveson T,Nicolson M,Coxon F,Middleton G,Daniel F,Oates J,Norman AR;Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med2008;358:36-46[PMID:18172173 DOI:10.1056/NEJMoa073149]
6 Kim GM,Jeung HC,Rha SY,Kim HS,Jung I,Nam BH,Lee KH,Chung HC.A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.Eur J Cancer 2012;48:518-526[PMID:22243774 DOI:10.1016/j.ejca.2011.12.017]
7 Yamada Y,Higuchi K,Nishikawa K,Gotoh M,Fuse N,Sugimoto N,Nishina T,Amagai K,Chin K,Niwa Y,Tsuji A,Imamura H,Tsuda M,Yasui H,Fujii H,Yamaguchi K,Yasui H,Hironaka S,Shimada K,Miwa H,Hamada C,Hyodo I.Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na?ve patients with advanced gastric cancer.Ann Oncol 2015;26:141-148[PMID:25316259 DOI:10.1093/annonc/mdu472]
8 Ter Veer E,Ngai LL,Valkenhoef GV,Mohammad NH,Anderegg MCJ,van Oijen MGH,van Laarhoven HWM.Capecitabine,5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer:A network meta-analysis.Sci Rep 2017;7:7142[PMID:28769123 DOI:10.1038/s41598-017-07750-3]
9 Ajani JA,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Marabotti C,Van Cutsem E;V-325 Study Group.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma:the V-325 Study Group.J Clin Oncol 2007;25:3205-3209[PMID:17664467 DOI:10.1200/JCO.2006.10.4968]
10 Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA;V325 Study Group.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997[PMID:17075117 DOI:10.1200/JCO.2006.06.8429]
11 Kang YK,Ryu MH,Yoo C,Chang HM,Yook JH,Oh ST,Kim BS,Kim TW.Phase I/II study of a combination of docetaxel,capecitabine,and cisplatin(DXP)as first-line chemotherapy in patients with advanced gastric cancer.Cancer Chemother Pharmacol 2011;67:1435-1443[PMID:20811894 DOI:10.1007/s00280-010-1444-4]
12 Sym SJ,Chang HM,Ryu MH,Lee JL,Kim TW,Yook JH,Oh ST,Kim BS,Kang YK.Neoadjuvant docetaxel,capecitabine and cisplatin(DXP)in patients with unresectable locally advanced or metastatic gastric cancer.Ann Surg Oncol 2010;17:1024-1032[PMID:19941081 DOI:10.1245/s10434-009-0838-1]
13 Maeda O,Matsuoka A,Miyahara R,Funasaka K,Hirooka Y,Fukaya M,Nagino M,Kodera Y,Goto H,Ando Y.Modified docetaxel,cisplatin and capecitabine for stage IV gastric cancer in Japanese patients:Afeasibility study.World J Gastroenterol 2017;23:1090-1097[PMID:28246483 DOI:10.3748/wjg.v23.i6.1090]
14 Koizumi W,Nakayama N,Tanabe S,Sasaki T,Higuchi K,Nishimura K,Takagi S,Azuma M,Ae T,Ishido K,Nakatani K,Naruke A,Katada C.A multicenter phase II study of combined chemotherapy with docetaxel,cisplatin,and S-1 in patients with unresectable or recurrent gastric cancer(KDOG 0601).Cancer Chemother Pharmacol 2012;69:407-413[PMID:21796483 DOI:10.1007/s00280-011-1701-1]
15 Ito S,Sano T,Mizusawa J,Takahari D,Katayama H,Katai H,Kawashima Y,Kinoshita T,Terashima M,Nashimoto A,Nakamori M,Onaya H,Sasako M.A phase II study of preoperative chemotherapy with docetaxel,cisplatin,and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis:JCOG1002.Gastric Cancer 2017;20:322-331[PMID:27299887 DOI:10.1007/s10120-016-0619-z]
16 Hosoda K,Azuma M,Katada C,Moriya H,Mieno H,Ishido K,Ema A,Ushiku H,Wada T,Washio M,Watanabe A,Higuchi K,Tanabe S,Koizumi W,Watanabe M,Yamashita K.A phase II study of neoadjuvant chemotherapy with docetaxel,cisplatin,and S-1,followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer:results of the KDOG1001 trial.Gastric Cancer2019;22:598-606[PMID:30284080 DOI:10.1007/s10120-018-0884-0]
17 Bang YJ,Van Cutsem E,Feyereislova A,Chung HC,Shen L,Sawaki A,Lordick F,Ohtsu A,Omuro Y,Satoh T,Aprile G,Kulikov E,Hill J,Lehle M,Rüschoff J,Kang YK;ToGA Trial Investigators.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial.Lancet 2010;376:687-697[PMID:20728210 DOI:10.1016/S0140-6736(10)61121-X]
18 Hecht JR,Bang YJ,Qin SK,Chung HC,Xu JM,Park JO,Jeziorski K,Shparyk Y,Hoff PM,Sobrero A,Salman P,Li J,Protsenko SA,Wainberg ZA,Buyse M,Afenjar K,HouéV,Garcia A,Kaneko T,Huang Y,Khan-Wasti S,Santillana S,Press MF,Slamon D.Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric,Esophageal,or Gastroesophageal Adenocarcinoma:TRIO-013/LOGiC--A Randomized Phase III Trial.JClin Oncol 2016;34:443-451[PMID:26628478 DOI:10.1200/JCO.2015.62.6598]
19 Satoh T,Xu RH,Chung HC,Sun GP,Doi T,Xu JM,Tsuji A,Omuro Y,Li J,Wang JW,Miwa H,Qin SK,Chung IJ,Yeh KH,Feng JF,Mukaiyama A,Kobayashi M,Ohtsu A,Bang YJ.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN--a randomized,phase III study.J Clin Oncol 2014;32:2039-2049[PMID:24868024 DOI:10.1200/JCO.2013.53.6136]
20 Thuss-Patience PC,Shah MA,Ohtsu A,Van Cutsem E,Ajani JA,Castro H,Mansoor W,Chung HC,Bodoky G,Shitara K,Phillips GDL,van der Horst T,Harle-Yge ML,Althaus BL,Kang YK.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma(GATSBY):an international randomised,open-label,adaptive,phase 2/3 study.Lancet Oncol 2017;18:640-653[PMID:28343975 DOI:10.1016/S1470-2045(17)30111-0]
21 Tabernero J,Hoff PM,Shen L,Ohtsu A,Shah MA,Cheng K,Song C,Wu H,Eng-Wong J,Kim K,Kang YK.Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastrooesophageal junction cancer(JACOB):final analysis of a double-blind,randomised,placebo-controlled phase 3 study.Lancet Oncol 2018;19:1372-1384[PMID:30217672 DOI:10.1016/S1470-2045(18)30481-9]
22 Ford HE,Marshall A,Bridgewater JA,Janowitz T,Coxon FY,Wadsley J,Mansoor W,Fyfe D,Madhusudan S,Middleton GW,Swinson D,Falk S,Chau I,Cunningham D,Kareclas P,Cook N,Blazeby JM,Dunn JA;COUGAR-02 Investigators.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02):an open-label,phase 3 randomised controlled trial.Lancet Oncol 2014;15:78-86[PMID:24332238 DOI:10.1016/S1470-2045(13)70549-7]
23 Thuss-Patience PC,Kretzschmar A,Bichev D,Deist T,Hinke A,Breithaupt K,Dogan Y,Gebauer B,Schumacher G,Reichardt P.Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie(AIO).Eur J Cancer 2011;47:2306-2314[PMID:21742485 DOI:10.1016/j.ejca.2011.06.002]
24 Kang JH,Lee SI,Lim DH,Park KW,Oh SY,Kwon HC,Hwang IG,Lee SC,Nam E,Shin DB,Lee J,Park JO,Park YS,Lim HY,Kang WK,Park SH.Salvage chemotherapy for pretreated gastric cancer:a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.J Clin Oncol 2012;30:1513-1518[PMID:22412140 DOI:10.1200/JCO.2011.39.4585]
25 Hironaka S,Ueda S,Yasui H,Nishina T,Tsuda M,Tsumura T,Sugimoto N,Shimodaira H,Tokunaga S,Moriwaki T,Esaki T,Nagase M,Fujitani K,Yamaguchi K,Ura T,Hamamoto Y,Morita S,Okamoto I,Boku N,Hyodo I.Randomized,open-label,phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial.J Clin Oncol 2013;31:4438-4444[PMID:24190112 DOI:10.1200/JCO.2012.48.5805]
26 Fuchs CS,Tomasek J,Yong CJ,Dumitru F,Passalacqua R,Goswami C,Safran H,Dos Santos LV,Aprile G,Ferry DR,Melichar B,Tehfe M,Topuzov E,Zalcberg JR,Chau I,Campbell W,Sivanandan C,Pikiel J,Koshiji M,Hsu Y,Liepa AM,Gao L,Schwartz JD,Tabernero J;REGARD Trial Investigators.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial.Lancet 2014;383:31-39[PMID:24094768 DOI:10.1016/S0140-6736(13)61719-5]
27 Wilke H,Muro K,Van Cutsem E,Oh SC,Bodoky G,Shimada Y,Hironaka S,Sugimoto N,Lipatov O,Kim TY,Cunningham D,Rougier P,Komatsu Y,Ajani J,Emig M,Carlesi R,Ferry D,Chandrawansa K,Schwartz JD,Ohtsu A;RAINBOW Study Group.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW):a double-blind,randomised phase 3 trial.Lancet Oncol 2014;15:1224-1235[PMID:25240821 DOI:10.1016/S1470-2045(14)70420-6]
28 Li J,Qin S,Xu J,Xiong J,Wu C,Bai Y,Liu W,Tong J,Liu Y,Xu R,Wang Z,Wang Q,Ouyang X,Yang Y,Ba Y,Liang J,Lin X,Luo D,Zheng R,Wang X,Sun G,Wang L,Zheng L,Guo H,Wu J,Xu N,Yang J,Zhang H,Cheng Y,Wang N,Chen L,Fan Z,Sun P,Yu H.Randomized,Double-Blind,PlaceboControlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.J Clin Oncol 2016;34:1448-1454[PMID:26884585 DOI:10.1200/JCO.2015.63.5995]
29 Shitara K,Doi T,Dvorkin M,Mansoor W,Arkenau HT,Prokharau A,Alsina M,Ghidini M,Faustino C,Gorbunova V,Zhavrid E,Nishikawa K,Hosokawa A,Yal??n?,Fujitani K,Beretta GD,Van Cutsem E,Winkler RE,Makris L,Ilson DH,Tabernero J.Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer(TAGS):a randomised,double-blind,placebo-controlled,phase 3 trial.Lancet Oncol 2018;19:1437-1448[PMID:30355453 DOI:10.1016/S1470-2045(18)30739-3]
30 Kang YK,Boku N,Satoh T,Ryu MH,Chao Y,Kato K,Chung HC,Chen JS,Muro K,Kang WK,Yeh KH,Yoshikawa T,Oh SC,Bai LY,Tamura T,Lee KW,Hamamoto Y,Kim JG,Chin K,Oh DY,Minashi K,Cho JY,Tsuda M,Chen LT.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial.Lancet 2017;390:2461-2471[PMID:28993052 DOI:10.1016/S0140-6736(17)31827-5]
31 Fuchs CS,Doi T,Jang RW,Muro K,Satoh T,Machado M,Sun W,Jalal SI,Shah MA,Metges JP,Garrido M,Golan T,Mandala M,Wainberg ZA,Catenacci DV,Ohtsu A,Shitara K,Geva R,Bleeker J,Ko AH,Ku G,Philip P,Enzinger PC,Bang YJ,Levitan D,Wang J,Rosales M,Dalal RP,Yoon HH.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer:Phase 2 Clinical KEYNOTE-059 Trial.JAMA Oncol 2018;4:e180013[PMID:29543932 DOI:10.1001/jamaoncol.2018.0013]
32 Shitara K,?zgüro?lu M,Bang YJ,Di Bartolomeo M,MandalàM,Ryu MH,Fornaro L,Olesiński T,Caglevic C,Chung HC,Muro K,Goekkurt E,Mansoor W,McDermott RS,Shacham-Shmueli E,Chen X,Mayo C,Kang SP,Ohtsu A,Fuchs CS;KEYNOTE-061 investigators.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer(KEYNOTE-061):a randomised,open-label,controlled,phase 3 trial.Lancet 2018;392:123-133[PMID:29880231 DOI:10.1016/S0140-6736(18)31257-1]
33 Ychou M,Boige V,Pignon JP,Conroy T,BouchéO,Lebreton G,Ducourtieux M,Bedenne L,Fabre JM,Saint-Aubert B,Genève J,Lasser P,Rougier P.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase III trial.J Clin Oncol 2011;29:1715-1721[PMID:21444866 DOI:10.1200/JCO.2010.33.0597]
34 Ando N,Iizuka T,Ide H,Ishida K,Shinoda M,Nishimaki T,Takiyama W,Watanabe H,Isono K,Aoyama N,Makuuchi H,Tanaka O,Yamana H,Ikeuchi S,Kabuto T,Nagai K,Shimada Y,Kinjo Y,Fukuda H;Japan Clinical Oncology Group.Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study--JCOG9204.J Clin Oncol 2003;21:4592-4596[PMID:14673047 DOI:10.1200/JCO.2003.12.095]
35 Ando N,Kato H,Igaki H,Shinoda M,Ozawa S,Shimizu H,Nakamura T,Yabusaki H,Aoyama N,Kurita A,Ikeda K,Kanda T,Tsujinaka T,Nakamura K,Fukuda H.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus(JCOG9907).Ann Surg Oncol 2012;19:68-74[PMID:21879261 DOI:10.1245/s10434-011-2049-9]
36 Tepper J,Krasna MJ,Niedzwiecki D,Hollis D,Reed CE,Goldberg R,Kiel K,Willett C,Sugarbaker D,Mayer R.Phase III trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781.J Clin Oncol 2008;26:1086-1092[PMID:18309943 DOI:10.1200/JCO.2007.12.9593]
37 Bedenne L,Michel P,BouchéO,Milan C,Mariette C,Conroy T,Pezet D,Roullet B,Seitz JF,Herr JP,Paillot B,Arveux P,Bonnetain F,Binquet C.Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus:FFCD 9102.J Clin Oncol 2007;25:1160-1168[PMID:17401004 DOI:10.1200/JCO.2005.04.7118]
38 van Hagen P,Hulshof MC,van Lanschot JJ,Steyerberg EW,van Berge Henegouwen MI,Wijnhoven BP,Richel DJ,Nieuwenhuijzen GA,Hospers GA,Bonenkamp JJ,Cuesta MA,Blaisse RJ,Busch OR,ten Kate FJ,Creemers GJ,Punt CJ,Plukker JT,Verheul HM,Spillenaar Bilgen EJ,van Dekken H,van der Sangen MJ,Rozema T,Biermann K,Beukema JC,Piet AH,van Rij CM,Reinders JG,Tilanus HW,van der Gaast A;CROSS Group.Preoperative chemoradiotherapy for esophageal or junctional cancer.N Engl J Med2012;366:2074-2084[PMID:22646630 DOI:10.1056/NEJMoa1112088]
39 Conroy T,Galais MP,Raoul JL,BouchéO,Gourgou-Bourgade S,Douillard JY,Etienne PL,Boige V,Martel-Lafay I,Michel P,Llacer-Moscardo C,Fran?ois E,Créhange G,Abdelghani MB,Juzyna B,Bedenne L,Adenis A;Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group.Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer(PRODIGE5/ACCORD17):final results of a randomised,phase 2/3 trial.Lancet Oncol 2014;15:305-314[PMID:24556041 DOI:10.1016/S1470-2045(14)70028-2]
40 Kato K,Muro K,Minashi K,Ohtsu A,Ishikura S,Boku N,Takiuchi H,Komatsu Y,Miyata Y,Fukuda H;Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group(JCOG).Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma:JCOG trial(JCOG 9906).Int J Radiat Oncol Biol Phys 2011;81:684-690[PMID:20932658 DOI:10.1016/j.ijrobp.2010.06.033]
41 Kato H,Sato A,Fukuda H,Kagami Y,Udagawa H,Togo A,Ando N,Tanaka O,Shinoda M,Yamana H,Ishikura S.A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma:Japan Clinical Oncology Group Study(JCOG9708).Jpn J Clin Oncol 2009;39:638-643[PMID:19549720DOI:10.1093/jjco/hyp069]
42 Ishida K,Ando N,Yamamoto S,Ide H,Shinoda M.Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus:a Japan Esophageal Oncology Group(JEOG)/Japan Clinical Oncology Group trial(JCOG9516).Jpn J Clin Oncol 2004;34:615-619[PMID:15591460 DOI:10.1093/jjco/hyh107]
43 Minsky BD,Pajak TF,Ginsberg RJ,Pisansky TM,Martenson J,Komaki R,Okawara G,Rosenthal SA,Kelsen DP.INT 0123(Radiation Therapy Oncology Group 94-05)phase III trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy.J Clin Oncol 2002;20:1167-1174[PMID:11870157 DOI:10.1200/JCO.2002.20.5.1167]
44 Muro K,Hamaguchi T,Ohtsu A,Boku N,Chin K,Hyodo I,Fujita H,Takiyama W,Ohtsu T.A phase IIstudy of single-agent docetaxel in patients with metastatic esophageal cancer.Ann Oncol 2004;15:955-959[PMID:15151954 DOI:10.1093/annonc/mdh231]
45 Kato K,Tahara M,Hironaka S,Muro K,Takiuchi H,Hamamoto Y,Imamoto H,Amano N,Seriu T.Aphase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.Cancer Chemother Pharmacol 2011;67:1265-1272[PMID:20703479 DOI:10.1007/s00280-010-1422-x]
46 Ilson DH,Wadleigh RG,Leichman LP,Kelsen DP.Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.Ann Oncol 2007;18:898-902[PMID:17351256 DOI:10.1093/annonc/mdm004]
47 Ohtsu A,Shah MA,Van Cutsem E,Rha SY,Sawaki A,Park SR,Lim HY,Yamada Y,Wu J,Langer B,Starnawski M,Kang YK.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a randomized,double-blind,placebo-controlled phase III study.J Clin Oncol2011;29:3968-3976[PMID:21844504 DOI:10.1200/JCO.2011.36.2236]
48 Waddell T,Chau I,Cunningham D,Gonzalez D,Okines AF,Okines C,Wotherspoon A,Saffery C,Middleton G,Wadsley J,Ferry D,Mansoor W,Crosby T,Coxon F,Smith D,Waters J,Iveson T,Falk S,Slater S,Peckitt C,Barbachano Y.Epirubicin,oxaliplatin,and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer(REAL3):a randomised,openlabel phase 3 trial.Lancet Oncol 2013;14:481-489[PMID:23594787 DOI:10.1016/S1470-2045(13)70096-2]
49 Dragovich T,McCoy S,Fenoglio-Preiser CM,Wang J,Benedetti JK,Baker AF,Hackett CB,Urba SG,Zaner KS,Blanke CD,Abbruzzese JL.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG 0127.J Clin Oncol 2006;24:4922-4927[PMID:17050876 DOI:10.1200/JCO.2006.07.1316]
50 Lordick F,Kang YK,Chung HC,Salman P,Oh SC,Bodoky G,Kurteva G,Volovat C,Moiseyenko VM,Gorbunova V,Park JO,Sawaki A,Celik I,G?tte H,MelezínkováH,Moehler M;Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND):a randomised,openlabel phase 3 trial.Lancet Oncol 2013;14:490-499[PMID:23594786 DOI:10.1016/S1470-2045(13)70102-5]
51 Enzinger PC,Burtness BA,Niedzwiecki D,Ye X,Douglas K,Ilson DH,Villaflor VM,Cohen SJ,Mayer RJ,Venook A,Benson AB,Goldberg RM.CALGB 80403(Alliance)/E1206:A Randomized Phase IIStudy of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.J Clin Oncol 2016;34:2736-2742[PMID:27382098 DOI:10.1200/JCO.2015.65.5092]
52 Crosby T,Hurt CN,Falk S,Gollins S,Mukherjee S,Staffurth J,Ray R,Bashir N,Bridgewater JA,Geh JI,Cunningham D,Blazeby J,Roy R,Maughan T,Griffiths G.Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer(SCOPE1):a multicentre,phase 2/3 randomised trial.Lancet Oncol 2013;14:627-637[PMID:23623280 DOI:10.1016/S1470-2045(13)70136-0]
53 Le DT,Durham JN,Smith KN,Wang H,Bartlett BR,Aulakh LK,Lu S,Kemberling H,Wilt C,Luber BS,Wong F,Azad NS,Rucki AA,Laheru D,Donehower R,Zaheer A,Fisher GA,Crocenzi TS,Lee JJ,Greten TF,Duffy AG,Ciombor KK,Eyring AD,Lam BH,Joe A,Kang SP,Holdhoff M,Danilova L,Cope L,Meyer C,Zhou S,Goldberg RM,Armstrong DK,Bever KM,Fader AN,Taube J,Housseau F,Spetzler D,Xiao N,Pardoll DM,Papadopoulos N,Kinzler KW,Eshleman JR,Vogelstein B,Anders RA,Diaz LA.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science 2017;357:409-413[PMID:28596308 DOI:10.1126/science.aan6733]
54 Le DT,Uram JN,Wang H,Bartlett BR,Kemberling H,Eyring AD,Skora AD,Luber BS,Azad NS,Laheru D,Biedrzycki B,Donehower RC,Zaheer A,Fisher GA,Crocenzi TS,Lee JJ,Duffy SM,Goldberg RM,de la Chapelle A,Koshiji M,Bhaijee F,Huebner T,Hruban RH,Wood LD,Cuka N,Pardoll DM,Papadopoulos N,Kinzler KW,Zhou S,Cornish TC,Taube JM,Anders RA,Eshleman JR,Vogelstein B,Diaz LA.PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med 2015;372:2509-2520[PMID:26028255 DOI:10.1056/NEJMoa1500596]
55 Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma.Nature 2014;513:202-209[PMID:25079317 DOI:10.1038/nature13480]
56 Cancer Genome Atlas Research Network.Analysis Working Group:Asan University;BC Cancer Agency;Brigham and Women’s Hospital;Broad Institute;Brown University;Case Western Reserve University;Dana-Farber Cancer Institute;Duke University;Greater Poland Cancer Centre;Harvard Medical School;Institute for Systems Biology;KU Leuven;Mayo Clinic;Memorial Sloan Kettering Cancer Center;National Cancer Institute;Nationwide Children’s Hospital;Stanford University;University of Alabama;University of Michigan;University of North Carolina;University of Pittsburgh;University of Rochester;University of Southern California;University of Texas MD Anderson Cancer Center;University of Washington;Van Andel Research Institute;Vanderbilt University;Washington University;Genome Sequencing Center:Broad Institute;Washington University in St.Louis;Genome Characterization Centers:BC Cancer Agency;Broad Institute;Harvard Medical School;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University;University of North Carolina;University of Southern California Epigenome Center;University of Texas MD Anderson Cancer Center;Van Andel Research Institute;Genome Data Analysis Centers:Broad Institute;Brown University:;Harvard Medical School;Institute for Systems Biology;Memorial Sloan Kettering Cancer Center;University of California Santa Cruz;University of Texas MD Anderson Cancer Center;Biospecimen Core Resource:International Genomics Consortium;Research Institute at Nationwide Children’s Hospital;Tissue Source Sites:Analytic Biologic Services;Asan Medical Center;Asterand Bioscience;Barretos Cancer Hospital;BioreclamationIVT;Botkin Municipal Clinic;Chonnam National University Medical School;Christiana Care Health System;Cureline;Duke University;Emory University;Erasmus University;Indiana University School of Medicine;Institute of Oncology of Moldova;International Genomics Consortium;Invidumed;Israelitisches Krankenhaus Hamburg;Keimyung University School of Medicine;Memorial Sloan Kettering Cancer Center;National Cancer Center Goyang;Ontario Tumour Bank;Peter MacCallum Cancer Centre;Pusan National University Medical School;Ribeir?o Preto Medical School;St.Joseph’s Hospital&Medical Center;St.Petersburg Academic University;Tayside Tissue Bank;University of Dundee;University of Kansas Medical Center;University of Michigan;University of North Carolina at Chapel Hill;University of Pittsburgh School of Medicine;University of Texas MD Anderson Cancer Center;Disease Working Group:Duke University;Memorial Sloan Kettering Cancer Center;National Cancer Institute;University of Texas MD Anderson Cancer Center;Yonsei University College of Medicine;Data Coordination Center:CSRA Inc;Project Team:National Institutes of Health.Integrated genomic characterization of oesophageal carcinoma.Nature 2017;541:169-175[PMID:28052061 DOI:10.1038/nature20805]
57 Smyth EC,Nyamundanda G,Cunningham D,Fontana E,Ragulan C,Tan IB,Lin SJ,Wotherspoon A,Nankivell M,Fassan M,Lampis A,Hahne JC,Davies AR,Lagergren J,Gossage JA,Maisey N,Green M,Zylstra JL,Allum WH,Langley RE,Tan P,Valeri N,Sadanandam A.A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.Ann Oncol 2018;29:2356-2362[PMID:30481267 DOI:10.1093/annonc/mdy407]
58 Maeda O,Ando T,Ohmiya N,Ishiguro K,Watanabe O,Miyahara R,Hibi Y,Nagai T,Yamada K,Goto H.Alteration of gene expression and DNA methylation in drug-resistant gastric cancer.Oncol Rep 2014;31:1883-1890[PMID:24504010 DOI:10.3892/or.2014.3014]
2 Koizumi W,Narahara H,Hara T,Takagane A,Akiya T,Takagi M,Miyashita K,Nishizaki T,Kobayashi O,Takiyama W,Toh Y,Nagaie T,Takagi S,Yamamura Y,Yanaoka K,Orita H,Takeuchi M.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial):a phase IIItrial.Lancet Oncol 2008;9:215-221[PMID:18282805 DOI:10.1016/S1470-2045(08)70035-4]
3 Al-Batran SE,Hartmann JT,Probst S,Schmalenberg H,Hollerbach S,Hofheinz R,Rethwisch V,Seipelt G,Homann N,Wilhelm G,Schuch G,Stoehlmacher J,Derigs HG,Hegewisch-Becker S,Grossmann J,Pauligk C,Atmaca A,Bokemeyer C,Knuth A,J?ger E;Arbeitsgemeinschaft Internistische Onkologie.Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin:a study of the Arbeitsgemeinschaft Internistische Onkologie.J Clin Oncol 2008;26:1435-1442[PMID:18349393 DOI:10.1200/jco.2007.13.9378]
4 Kang YK,Kang WK,Shin DB,Chen J,Xiong J,Wang J,Lichinitser M,Guan Z,Khasanov R,Zheng L,Philco-Salas M,Suarez T,Santamaria J,Forster G,McCloud PI.Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phase IIInoninferiority trial.Ann Oncol 2009;20:666-673[PMID:19153121 DOI:10.1093/annonc/mdn717]
5 Cunningham D,Starling N,Rao S,Iveson T,Nicolson M,Coxon F,Middleton G,Daniel F,Oates J,Norman AR;Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med2008;358:36-46[PMID:18172173 DOI:10.1056/NEJMoa073149]
6 Kim GM,Jeung HC,Rha SY,Kim HS,Jung I,Nam BH,Lee KH,Chung HC.A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.Eur J Cancer 2012;48:518-526[PMID:22243774 DOI:10.1016/j.ejca.2011.12.017]
7 Yamada Y,Higuchi K,Nishikawa K,Gotoh M,Fuse N,Sugimoto N,Nishina T,Amagai K,Chin K,Niwa Y,Tsuji A,Imamura H,Tsuda M,Yasui H,Fujii H,Yamaguchi K,Yasui H,Hironaka S,Shimada K,Miwa H,Hamada C,Hyodo I.Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na?ve patients with advanced gastric cancer.Ann Oncol 2015;26:141-148[PMID:25316259 DOI:10.1093/annonc/mdu472]
8 Ter Veer E,Ngai LL,Valkenhoef GV,Mohammad NH,Anderegg MCJ,van Oijen MGH,van Laarhoven HWM.Capecitabine,5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer:A network meta-analysis.Sci Rep 2017;7:7142[PMID:28769123 DOI:10.1038/s41598-017-07750-3]
9 Ajani JA,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Marabotti C,Van Cutsem E;V-325 Study Group.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma:the V-325 Study Group.J Clin Oncol 2007;25:3205-3209[PMID:17664467 DOI:10.1200/JCO.2006.10.4968]
10 Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA;V325 Study Group.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997[PMID:17075117 DOI:10.1200/JCO.2006.06.8429]
11 Kang YK,Ryu MH,Yoo C,Chang HM,Yook JH,Oh ST,Kim BS,Kim TW.Phase I/II study of a combination of docetaxel,capecitabine,and cisplatin(DXP)as first-line chemotherapy in patients with advanced gastric cancer.Cancer Chemother Pharmacol 2011;67:1435-1443[PMID:20811894 DOI:10.1007/s00280-010-1444-4]
12 Sym SJ,Chang HM,Ryu MH,Lee JL,Kim TW,Yook JH,Oh ST,Kim BS,Kang YK.Neoadjuvant docetaxel,capecitabine and cisplatin(DXP)in patients with unresectable locally advanced or metastatic gastric cancer.Ann Surg Oncol 2010;17:1024-1032[PMID:19941081 DOI:10.1245/s10434-009-0838-1]
13 Maeda O,Matsuoka A,Miyahara R,Funasaka K,Hirooka Y,Fukaya M,Nagino M,Kodera Y,Goto H,Ando Y.Modified docetaxel,cisplatin and capecitabine for stage IV gastric cancer in Japanese patients:Afeasibility study.World J Gastroenterol 2017;23:1090-1097[PMID:28246483 DOI:10.3748/wjg.v23.i6.1090]
14 Koizumi W,Nakayama N,Tanabe S,Sasaki T,Higuchi K,Nishimura K,Takagi S,Azuma M,Ae T,Ishido K,Nakatani K,Naruke A,Katada C.A multicenter phase II study of combined chemotherapy with docetaxel,cisplatin,and S-1 in patients with unresectable or recurrent gastric cancer(KDOG 0601).Cancer Chemother Pharmacol 2012;69:407-413[PMID:21796483 DOI:10.1007/s00280-011-1701-1]
15 Ito S,Sano T,Mizusawa J,Takahari D,Katayama H,Katai H,Kawashima Y,Kinoshita T,Terashima M,Nashimoto A,Nakamori M,Onaya H,Sasako M.A phase II study of preoperative chemotherapy with docetaxel,cisplatin,and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis:JCOG1002.Gastric Cancer 2017;20:322-331[PMID:27299887 DOI:10.1007/s10120-016-0619-z]
16 Hosoda K,Azuma M,Katada C,Moriya H,Mieno H,Ishido K,Ema A,Ushiku H,Wada T,Washio M,Watanabe A,Higuchi K,Tanabe S,Koizumi W,Watanabe M,Yamashita K.A phase II study of neoadjuvant chemotherapy with docetaxel,cisplatin,and S-1,followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer:results of the KDOG1001 trial.Gastric Cancer2019;22:598-606[PMID:30284080 DOI:10.1007/s10120-018-0884-0]
17 Bang YJ,Van Cutsem E,Feyereislova A,Chung HC,Shen L,Sawaki A,Lordick F,Ohtsu A,Omuro Y,Satoh T,Aprile G,Kulikov E,Hill J,Lehle M,Rüschoff J,Kang YK;ToGA Trial Investigators.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial.Lancet 2010;376:687-697[PMID:20728210 DOI:10.1016/S0140-6736(10)61121-X]
18 Hecht JR,Bang YJ,Qin SK,Chung HC,Xu JM,Park JO,Jeziorski K,Shparyk Y,Hoff PM,Sobrero A,Salman P,Li J,Protsenko SA,Wainberg ZA,Buyse M,Afenjar K,HouéV,Garcia A,Kaneko T,Huang Y,Khan-Wasti S,Santillana S,Press MF,Slamon D.Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric,Esophageal,or Gastroesophageal Adenocarcinoma:TRIO-013/LOGiC--A Randomized Phase III Trial.JClin Oncol 2016;34:443-451[PMID:26628478 DOI:10.1200/JCO.2015.62.6598]
19 Satoh T,Xu RH,Chung HC,Sun GP,Doi T,Xu JM,Tsuji A,Omuro Y,Li J,Wang JW,Miwa H,Qin SK,Chung IJ,Yeh KH,Feng JF,Mukaiyama A,Kobayashi M,Ohtsu A,Bang YJ.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN--a randomized,phase III study.J Clin Oncol 2014;32:2039-2049[PMID:24868024 DOI:10.1200/JCO.2013.53.6136]
20 Thuss-Patience PC,Shah MA,Ohtsu A,Van Cutsem E,Ajani JA,Castro H,Mansoor W,Chung HC,Bodoky G,Shitara K,Phillips GDL,van der Horst T,Harle-Yge ML,Althaus BL,Kang YK.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma(GATSBY):an international randomised,open-label,adaptive,phase 2/3 study.Lancet Oncol 2017;18:640-653[PMID:28343975 DOI:10.1016/S1470-2045(17)30111-0]
21 Tabernero J,Hoff PM,Shen L,Ohtsu A,Shah MA,Cheng K,Song C,Wu H,Eng-Wong J,Kim K,Kang YK.Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastrooesophageal junction cancer(JACOB):final analysis of a double-blind,randomised,placebo-controlled phase 3 study.Lancet Oncol 2018;19:1372-1384[PMID:30217672 DOI:10.1016/S1470-2045(18)30481-9]
22 Ford HE,Marshall A,Bridgewater JA,Janowitz T,Coxon FY,Wadsley J,Mansoor W,Fyfe D,Madhusudan S,Middleton GW,Swinson D,Falk S,Chau I,Cunningham D,Kareclas P,Cook N,Blazeby JM,Dunn JA;COUGAR-02 Investigators.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02):an open-label,phase 3 randomised controlled trial.Lancet Oncol 2014;15:78-86[PMID:24332238 DOI:10.1016/S1470-2045(13)70549-7]
23 Thuss-Patience PC,Kretzschmar A,Bichev D,Deist T,Hinke A,Breithaupt K,Dogan Y,Gebauer B,Schumacher G,Reichardt P.Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie(AIO).Eur J Cancer 2011;47:2306-2314[PMID:21742485 DOI:10.1016/j.ejca.2011.06.002]
24 Kang JH,Lee SI,Lim DH,Park KW,Oh SY,Kwon HC,Hwang IG,Lee SC,Nam E,Shin DB,Lee J,Park JO,Park YS,Lim HY,Kang WK,Park SH.Salvage chemotherapy for pretreated gastric cancer:a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.J Clin Oncol 2012;30:1513-1518[PMID:22412140 DOI:10.1200/JCO.2011.39.4585]
25 Hironaka S,Ueda S,Yasui H,Nishina T,Tsuda M,Tsumura T,Sugimoto N,Shimodaira H,Tokunaga S,Moriwaki T,Esaki T,Nagase M,Fujitani K,Yamaguchi K,Ura T,Hamamoto Y,Morita S,Okamoto I,Boku N,Hyodo I.Randomized,open-label,phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial.J Clin Oncol 2013;31:4438-4444[PMID:24190112 DOI:10.1200/JCO.2012.48.5805]
26 Fuchs CS,Tomasek J,Yong CJ,Dumitru F,Passalacqua R,Goswami C,Safran H,Dos Santos LV,Aprile G,Ferry DR,Melichar B,Tehfe M,Topuzov E,Zalcberg JR,Chau I,Campbell W,Sivanandan C,Pikiel J,Koshiji M,Hsu Y,Liepa AM,Gao L,Schwartz JD,Tabernero J;REGARD Trial Investigators.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial.Lancet 2014;383:31-39[PMID:24094768 DOI:10.1016/S0140-6736(13)61719-5]
27 Wilke H,Muro K,Van Cutsem E,Oh SC,Bodoky G,Shimada Y,Hironaka S,Sugimoto N,Lipatov O,Kim TY,Cunningham D,Rougier P,Komatsu Y,Ajani J,Emig M,Carlesi R,Ferry D,Chandrawansa K,Schwartz JD,Ohtsu A;RAINBOW Study Group.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW):a double-blind,randomised phase 3 trial.Lancet Oncol 2014;15:1224-1235[PMID:25240821 DOI:10.1016/S1470-2045(14)70420-6]
28 Li J,Qin S,Xu J,Xiong J,Wu C,Bai Y,Liu W,Tong J,Liu Y,Xu R,Wang Z,Wang Q,Ouyang X,Yang Y,Ba Y,Liang J,Lin X,Luo D,Zheng R,Wang X,Sun G,Wang L,Zheng L,Guo H,Wu J,Xu N,Yang J,Zhang H,Cheng Y,Wang N,Chen L,Fan Z,Sun P,Yu H.Randomized,Double-Blind,PlaceboControlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.J Clin Oncol 2016;34:1448-1454[PMID:26884585 DOI:10.1200/JCO.2015.63.5995]
29 Shitara K,Doi T,Dvorkin M,Mansoor W,Arkenau HT,Prokharau A,Alsina M,Ghidini M,Faustino C,Gorbunova V,Zhavrid E,Nishikawa K,Hosokawa A,Yal??n?,Fujitani K,Beretta GD,Van Cutsem E,Winkler RE,Makris L,Ilson DH,Tabernero J.Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer(TAGS):a randomised,double-blind,placebo-controlled,phase 3 trial.Lancet Oncol 2018;19:1437-1448[PMID:30355453 DOI:10.1016/S1470-2045(18)30739-3]
30 Kang YK,Boku N,Satoh T,Ryu MH,Chao Y,Kato K,Chung HC,Chen JS,Muro K,Kang WK,Yeh KH,Yoshikawa T,Oh SC,Bai LY,Tamura T,Lee KW,Hamamoto Y,Kim JG,Chin K,Oh DY,Minashi K,Cho JY,Tsuda M,Chen LT.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial.Lancet 2017;390:2461-2471[PMID:28993052 DOI:10.1016/S0140-6736(17)31827-5]
31 Fuchs CS,Doi T,Jang RW,Muro K,Satoh T,Machado M,Sun W,Jalal SI,Shah MA,Metges JP,Garrido M,Golan T,Mandala M,Wainberg ZA,Catenacci DV,Ohtsu A,Shitara K,Geva R,Bleeker J,Ko AH,Ku G,Philip P,Enzinger PC,Bang YJ,Levitan D,Wang J,Rosales M,Dalal RP,Yoon HH.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer:Phase 2 Clinical KEYNOTE-059 Trial.JAMA Oncol 2018;4:e180013[PMID:29543932 DOI:10.1001/jamaoncol.2018.0013]
32 Shitara K,?zgüro?lu M,Bang YJ,Di Bartolomeo M,MandalàM,Ryu MH,Fornaro L,Olesiński T,Caglevic C,Chung HC,Muro K,Goekkurt E,Mansoor W,McDermott RS,Shacham-Shmueli E,Chen X,Mayo C,Kang SP,Ohtsu A,Fuchs CS;KEYNOTE-061 investigators.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer(KEYNOTE-061):a randomised,open-label,controlled,phase 3 trial.Lancet 2018;392:123-133[PMID:29880231 DOI:10.1016/S0140-6736(18)31257-1]
33 Ychou M,Boige V,Pignon JP,Conroy T,BouchéO,Lebreton G,Ducourtieux M,Bedenne L,Fabre JM,Saint-Aubert B,Genève J,Lasser P,Rougier P.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase III trial.J Clin Oncol 2011;29:1715-1721[PMID:21444866 DOI:10.1200/JCO.2010.33.0597]
34 Ando N,Iizuka T,Ide H,Ishida K,Shinoda M,Nishimaki T,Takiyama W,Watanabe H,Isono K,Aoyama N,Makuuchi H,Tanaka O,Yamana H,Ikeuchi S,Kabuto T,Nagai K,Shimada Y,Kinjo Y,Fukuda H;Japan Clinical Oncology Group.Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study--JCOG9204.J Clin Oncol 2003;21:4592-4596[PMID:14673047 DOI:10.1200/JCO.2003.12.095]
35 Ando N,Kato H,Igaki H,Shinoda M,Ozawa S,Shimizu H,Nakamura T,Yabusaki H,Aoyama N,Kurita A,Ikeda K,Kanda T,Tsujinaka T,Nakamura K,Fukuda H.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus(JCOG9907).Ann Surg Oncol 2012;19:68-74[PMID:21879261 DOI:10.1245/s10434-011-2049-9]
36 Tepper J,Krasna MJ,Niedzwiecki D,Hollis D,Reed CE,Goldberg R,Kiel K,Willett C,Sugarbaker D,Mayer R.Phase III trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781.J Clin Oncol 2008;26:1086-1092[PMID:18309943 DOI:10.1200/JCO.2007.12.9593]
37 Bedenne L,Michel P,BouchéO,Milan C,Mariette C,Conroy T,Pezet D,Roullet B,Seitz JF,Herr JP,Paillot B,Arveux P,Bonnetain F,Binquet C.Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus:FFCD 9102.J Clin Oncol 2007;25:1160-1168[PMID:17401004 DOI:10.1200/JCO.2005.04.7118]
38 van Hagen P,Hulshof MC,van Lanschot JJ,Steyerberg EW,van Berge Henegouwen MI,Wijnhoven BP,Richel DJ,Nieuwenhuijzen GA,Hospers GA,Bonenkamp JJ,Cuesta MA,Blaisse RJ,Busch OR,ten Kate FJ,Creemers GJ,Punt CJ,Plukker JT,Verheul HM,Spillenaar Bilgen EJ,van Dekken H,van der Sangen MJ,Rozema T,Biermann K,Beukema JC,Piet AH,van Rij CM,Reinders JG,Tilanus HW,van der Gaast A;CROSS Group.Preoperative chemoradiotherapy for esophageal or junctional cancer.N Engl J Med2012;366:2074-2084[PMID:22646630 DOI:10.1056/NEJMoa1112088]
39 Conroy T,Galais MP,Raoul JL,BouchéO,Gourgou-Bourgade S,Douillard JY,Etienne PL,Boige V,Martel-Lafay I,Michel P,Llacer-Moscardo C,Fran?ois E,Créhange G,Abdelghani MB,Juzyna B,Bedenne L,Adenis A;Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group.Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer(PRODIGE5/ACCORD17):final results of a randomised,phase 2/3 trial.Lancet Oncol 2014;15:305-314[PMID:24556041 DOI:10.1016/S1470-2045(14)70028-2]
40 Kato K,Muro K,Minashi K,Ohtsu A,Ishikura S,Boku N,Takiuchi H,Komatsu Y,Miyata Y,Fukuda H;Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group(JCOG).Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma:JCOG trial(JCOG 9906).Int J Radiat Oncol Biol Phys 2011;81:684-690[PMID:20932658 DOI:10.1016/j.ijrobp.2010.06.033]
41 Kato H,Sato A,Fukuda H,Kagami Y,Udagawa H,Togo A,Ando N,Tanaka O,Shinoda M,Yamana H,Ishikura S.A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma:Japan Clinical Oncology Group Study(JCOG9708).Jpn J Clin Oncol 2009;39:638-643[PMID:19549720DOI:10.1093/jjco/hyp069]
42 Ishida K,Ando N,Yamamoto S,Ide H,Shinoda M.Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus:a Japan Esophageal Oncology Group(JEOG)/Japan Clinical Oncology Group trial(JCOG9516).Jpn J Clin Oncol 2004;34:615-619[PMID:15591460 DOI:10.1093/jjco/hyh107]
43 Minsky BD,Pajak TF,Ginsberg RJ,Pisansky TM,Martenson J,Komaki R,Okawara G,Rosenthal SA,Kelsen DP.INT 0123(Radiation Therapy Oncology Group 94-05)phase III trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy.J Clin Oncol 2002;20:1167-1174[PMID:11870157 DOI:10.1200/JCO.2002.20.5.1167]
44 Muro K,Hamaguchi T,Ohtsu A,Boku N,Chin K,Hyodo I,Fujita H,Takiyama W,Ohtsu T.A phase IIstudy of single-agent docetaxel in patients with metastatic esophageal cancer.Ann Oncol 2004;15:955-959[PMID:15151954 DOI:10.1093/annonc/mdh231]
45 Kato K,Tahara M,Hironaka S,Muro K,Takiuchi H,Hamamoto Y,Imamoto H,Amano N,Seriu T.Aphase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.Cancer Chemother Pharmacol 2011;67:1265-1272[PMID:20703479 DOI:10.1007/s00280-010-1422-x]
46 Ilson DH,Wadleigh RG,Leichman LP,Kelsen DP.Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.Ann Oncol 2007;18:898-902[PMID:17351256 DOI:10.1093/annonc/mdm004]
47 Ohtsu A,Shah MA,Van Cutsem E,Rha SY,Sawaki A,Park SR,Lim HY,Yamada Y,Wu J,Langer B,Starnawski M,Kang YK.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a randomized,double-blind,placebo-controlled phase III study.J Clin Oncol2011;29:3968-3976[PMID:21844504 DOI:10.1200/JCO.2011.36.2236]
48 Waddell T,Chau I,Cunningham D,Gonzalez D,Okines AF,Okines C,Wotherspoon A,Saffery C,Middleton G,Wadsley J,Ferry D,Mansoor W,Crosby T,Coxon F,Smith D,Waters J,Iveson T,Falk S,Slater S,Peckitt C,Barbachano Y.Epirubicin,oxaliplatin,and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer(REAL3):a randomised,openlabel phase 3 trial.Lancet Oncol 2013;14:481-489[PMID:23594787 DOI:10.1016/S1470-2045(13)70096-2]
49 Dragovich T,McCoy S,Fenoglio-Preiser CM,Wang J,Benedetti JK,Baker AF,Hackett CB,Urba SG,Zaner KS,Blanke CD,Abbruzzese JL.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG 0127.J Clin Oncol 2006;24:4922-4927[PMID:17050876 DOI:10.1200/JCO.2006.07.1316]
50 Lordick F,Kang YK,Chung HC,Salman P,Oh SC,Bodoky G,Kurteva G,Volovat C,Moiseyenko VM,Gorbunova V,Park JO,Sawaki A,Celik I,G?tte H,MelezínkováH,Moehler M;Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND):a randomised,openlabel phase 3 trial.Lancet Oncol 2013;14:490-499[PMID:23594786 DOI:10.1016/S1470-2045(13)70102-5]
51 Enzinger PC,Burtness BA,Niedzwiecki D,Ye X,Douglas K,Ilson DH,Villaflor VM,Cohen SJ,Mayer RJ,Venook A,Benson AB,Goldberg RM.CALGB 80403(Alliance)/E1206:A Randomized Phase IIStudy of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.J Clin Oncol 2016;34:2736-2742[PMID:27382098 DOI:10.1200/JCO.2015.65.5092]
52 Crosby T,Hurt CN,Falk S,Gollins S,Mukherjee S,Staffurth J,Ray R,Bashir N,Bridgewater JA,Geh JI,Cunningham D,Blazeby J,Roy R,Maughan T,Griffiths G.Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer(SCOPE1):a multicentre,phase 2/3 randomised trial.Lancet Oncol 2013;14:627-637[PMID:23623280 DOI:10.1016/S1470-2045(13)70136-0]
53 Le DT,Durham JN,Smith KN,Wang H,Bartlett BR,Aulakh LK,Lu S,Kemberling H,Wilt C,Luber BS,Wong F,Azad NS,Rucki AA,Laheru D,Donehower R,Zaheer A,Fisher GA,Crocenzi TS,Lee JJ,Greten TF,Duffy AG,Ciombor KK,Eyring AD,Lam BH,Joe A,Kang SP,Holdhoff M,Danilova L,Cope L,Meyer C,Zhou S,Goldberg RM,Armstrong DK,Bever KM,Fader AN,Taube J,Housseau F,Spetzler D,Xiao N,Pardoll DM,Papadopoulos N,Kinzler KW,Eshleman JR,Vogelstein B,Anders RA,Diaz LA.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science 2017;357:409-413[PMID:28596308 DOI:10.1126/science.aan6733]
54 Le DT,Uram JN,Wang H,Bartlett BR,Kemberling H,Eyring AD,Skora AD,Luber BS,Azad NS,Laheru D,Biedrzycki B,Donehower RC,Zaheer A,Fisher GA,Crocenzi TS,Lee JJ,Duffy SM,Goldberg RM,de la Chapelle A,Koshiji M,Bhaijee F,Huebner T,Hruban RH,Wood LD,Cuka N,Pardoll DM,Papadopoulos N,Kinzler KW,Zhou S,Cornish TC,Taube JM,Anders RA,Eshleman JR,Vogelstein B,Diaz LA.PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med 2015;372:2509-2520[PMID:26028255 DOI:10.1056/NEJMoa1500596]
55 Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma.Nature 2014;513:202-209[PMID:25079317 DOI:10.1038/nature13480]
56 Cancer Genome Atlas Research Network.Analysis Working Group:Asan University;BC Cancer Agency;Brigham and Women’s Hospital;Broad Institute;Brown University;Case Western Reserve University;Dana-Farber Cancer Institute;Duke University;Greater Poland Cancer Centre;Harvard Medical School;Institute for Systems Biology;KU Leuven;Mayo Clinic;Memorial Sloan Kettering Cancer Center;National Cancer Institute;Nationwide Children’s Hospital;Stanford University;University of Alabama;University of Michigan;University of North Carolina;University of Pittsburgh;University of Rochester;University of Southern California;University of Texas MD Anderson Cancer Center;University of Washington;Van Andel Research Institute;Vanderbilt University;Washington University;Genome Sequencing Center:Broad Institute;Washington University in St.Louis;Genome Characterization Centers:BC Cancer Agency;Broad Institute;Harvard Medical School;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University;University of North Carolina;University of Southern California Epigenome Center;University of Texas MD Anderson Cancer Center;Van Andel Research Institute;Genome Data Analysis Centers:Broad Institute;Brown University:;Harvard Medical School;Institute for Systems Biology;Memorial Sloan Kettering Cancer Center;University of California Santa Cruz;University of Texas MD Anderson Cancer Center;Biospecimen Core Resource:International Genomics Consortium;Research Institute at Nationwide Children’s Hospital;Tissue Source Sites:Analytic Biologic Services;Asan Medical Center;Asterand Bioscience;Barretos Cancer Hospital;BioreclamationIVT;Botkin Municipal Clinic;Chonnam National University Medical School;Christiana Care Health System;Cureline;Duke University;Emory University;Erasmus University;Indiana University School of Medicine;Institute of Oncology of Moldova;International Genomics Consortium;Invidumed;Israelitisches Krankenhaus Hamburg;Keimyung University School of Medicine;Memorial Sloan Kettering Cancer Center;National Cancer Center Goyang;Ontario Tumour Bank;Peter MacCallum Cancer Centre;Pusan National University Medical School;Ribeir?o Preto Medical School;St.Joseph’s Hospital&Medical Center;St.Petersburg Academic University;Tayside Tissue Bank;University of Dundee;University of Kansas Medical Center;University of Michigan;University of North Carolina at Chapel Hill;University of Pittsburgh School of Medicine;University of Texas MD Anderson Cancer Center;Disease Working Group:Duke University;Memorial Sloan Kettering Cancer Center;National Cancer Institute;University of Texas MD Anderson Cancer Center;Yonsei University College of Medicine;Data Coordination Center:CSRA Inc;Project Team:National Institutes of Health.Integrated genomic characterization of oesophageal carcinoma.Nature 2017;541:169-175[PMID:28052061 DOI:10.1038/nature20805]
57 Smyth EC,Nyamundanda G,Cunningham D,Fontana E,Ragulan C,Tan IB,Lin SJ,Wotherspoon A,Nankivell M,Fassan M,Lampis A,Hahne JC,Davies AR,Lagergren J,Gossage JA,Maisey N,Green M,Zylstra JL,Allum WH,Langley RE,Tan P,Valeri N,Sadanandam A.A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.Ann Oncol 2018;29:2356-2362[PMID:30481267 DOI:10.1093/annonc/mdy407]
58 Maeda O,Ando T,Ohmiya N,Ishiguro K,Watanabe O,Miyahara R,Hibi Y,Nagai T,Yamada K,Goto H.Alteration of gene expression and DNA methylation in drug-resistant gastric cancer.Oncol Rep 2014;31:1883-1890[PMID:24504010 DOI:10.3892/or.2014.3014]